773
Views
18
CrossRef citations to date
0
Altmetric
Original Article

Retinol binding protein 4: An adipokine associated with intra-amniotic infection/inflammation

, , , , , , , , , , , , & show all
Pages 111-119 | Received 17 Feb 2009, Accepted 10 Mar 2009, Published online: 30 Sep 2009

Abstract

Objective. Retinol binding protein 4 (RBP4), a specific carrier for retinol in the blood, is a novel adipokine that has been implicated in the pathophysiology of insulin resistance, and its gene expression has been associated with adipose tissue inflammation. Recently, proteomic profiling of amniotic fluid (AF) from women with preterm labor (PTL) revealed over-expression of RBP4 in those who delivered preterm. The aim of this study was to determine whether RBP4 is present in AF, and if its concentrations change with gestational age, in the presence of labor, and intra-amniotic infection/inflammation (IAI) in patients with spontaneous PTL.

Study design. This cross-sectional study included pregnant women in the following groups: (1) mid-trimester (n = 30); (2) term not in labor (n = 31); (3) term in labor (n = 30); (4) spontaneous PTL without IAI who delivered at term (n = 60); (5) PTL without IAI who delivered preterm (n = 64); and (6) PTL with IAI (n = 56). RBP4 concentrations in AF were determined by ELISA. Non-parametric statistics were used for analyses.

Results. (1) RBP4 was detected in all AF samples; (2) among patients with PTL, women with IAI had a higher median AF RBP4 concentration than those without IAI who delivered preterm (1268.9 ng/ml, interquartile range (IQR) 900.3–1970.1 vs. 815.8 ng/ml, IQR 592.4–1098.1; p < 0.001) and at term (828.7 ng/ml, IQR 499.7–1119.6; p < 0.001); (3) the median AF RBP4 concentration was higher in women in the mid-trimester than in those at term not in labor (1861.1 ng/ml, IQR 1486.2–2034.3 vs. 766.1 ng/ml, IQR 608.5–1154.1; p < 0.0001; (4) the median AF RBP4 concentration did not differ significantly between patients with PTL without IAI who delivered preterm and those who delivered at term (p = 0.7); and (5) among women at term, the median AF RBP4 concentrations was not significantly different between those in labor and those not in labor (p = 0.4).

Conclusions. RBP4 is a physiologic constituent of the AF. Among patients with PTL, the median AF concentration of immunoreactive RBP4 is elevated in pregnancies complicated by IAI. These results suggest that RBP4 may participate in the host response against IAI.

Introduction

Adipokines are adipocyte-derived cytokines that provide a link between obesity, insulin resistance and obesity-related inflammatory disorders [Citation1]. This family of biologically active molecules includes peptides and proteins such as leptin (the first adipokine to be discovered [Citation2]), adiponectin, visfatin and resistin, as well as other cytokines and chemokines (i.e. tumor necrosis factor, interleukin (IL)-6, IL-1, and monocyte chemotactic protein (MCP)-1) which were described to be secreted by adipose tissue [Citation1]. Retinol binding protein 4 (RBP4) [Citation3], has recently been added to the rapidly expanding list of adipokines [Citation4–6].

RBP4 belongs to the lipocalin family and is a specific carrier for retinol (vitamin A) in the blood. Until recently, its only function was thought to be the delivery of retinol to peripheral tissues. However, in 2005 Yang et al. [Citation3] rekindled interest in this molecule by describing RBP4 as a novel adipokine. Using global gene expression analysis in an adipocye-specific Glut4 knockout mouse model, RBP4 was found to be over-expressed in adipose tissue, and implicated in the pathophysiology of insulin resistance [Citation3]. Indeed, increased circulating RBP4 concentrations have been reported in patients with diabetes [Citation3]. Moreover, high plasma concentrations of RBP4 precede the development of overt diabetes [Citation7,Citation8]. In contrast, other investigators, have not established an association between plasma RBP4 concentrations and insulin resistance [Citation9,Citation10]. Furthermore, emerging evidence suggests that RBP4 plays a role in the inflammatory response. Indeed, in non-diabetic human subjects, RBP4 gene expression was found to be strongly associated with inflammatory markers (i.e. CD68 and MCP-1) of adipose tissue [Citation10].

Recently, our group has demonstrated that increased AF concentrations of adipokines, such as visfatin [Citation11] and resistin, [Citation12] are associated with intra-amniotic infection/inflammation (IAI). Furthermore, proteomic profiling of the AF of patients with spontaneous preterm labor (PTL) revealed that RBP4 is over-expressed in patients who delivered preterm when compared with those with an episode of PTL who delivered at term [Citation13]. Although this increased expression was noted regardless of the presence or absence of IAI, it was more profound in microbial invasion of the amniotic cavity [Citation13].

Thus, the aim of this study was to determine whether the AF concentrations of RBP4 change with advancing gestational age, spontaneous labor at term, and in the presence of IAI in patients with spontaneous PTL and intact membranes.

Materials and methods

Study design and population

A cross-sectional study was conducted by searching our clinical database and bank of biological specimens, and included pregnant women in the following groups: (1) women in the mid-trimester of pregnancy (14–18 weeks) who underwent amniocentesis for genetic indications and delivered a normal neonate at term (n = 30); (2) normal pregnant women at term with (n = 30) and without spontaneous labor (n = 31); (3) patients with an episode of spontaneous PTL and intact membranes who were classified into: (a) PTL without IAI who delivered at term (n = 60); (b) PTL without IAI who delivered preterm (n = 64); and (c) PTL with IAI (n = 56).

All participants provided written informed consent prior to the collection of AF. The collection of AF and its utilization for research purposes was approved by the Institutional Review Boards of the participating institutions and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD/NIH/DHHS). Many of these samples have been used previously to study the biology of inflammation, hemostasis, angiogenesis regulation and growth factor concentrations in normal pregnant women and those with pregnancy complications.

Definitions

Patients were considered to have a normal pregnancy outcome if they did not have obstetrical complications and delivered at term (≥37 weeks) a healthy neonate with appropriate birthweight for gestational age [Citation14,Citation15]. Spontaneous PTL was defined by the presence of regular uterine contractions (occurring at a frequency of at least 2 every 10 min) associated with cervical change that required hospitalization before 37 completed weeks of gestation. Preterm delivery was defined as delivery before 37 completed weeks of gestation. Intra-amniotic infection was defined as a positive AF culture for micro-organisms. Intra-amniotic inflammation was diagnosed by an AF IL-6 concentration ≥2.6 ng/ml [Citation16]. Histologic chorioamnionitis was diagnosed based on the presence of inflammatory cells in the chorionic plate and/or chorioamniotic membranes, and acute funisitis was diagnosed by the presence of neutrophils in the wall of the umbilical vessels and/or Wharton's jelly, using the criteria previously described [Citation17,Citation18].

Amniotic fluid sample collection

AF samples were obtained by transabdominal amniocenteses performed for genetic indication, evaluation of microbial status of the amniotic cavity, and/or assessment of fetal lung maturity in patients approaching term. Women at term not in labor underwent amniocentesis for the assessment of fetal lung maturity prior to cesarean section. Women at term in labor consisted of women who were suspected to have PTL because of uncertain dates and had an amniocentesis for the assessment of microbial invasion of the amniotic cavity and fetal lung maturity. These patients were retrospectively considered to be in labor at term if all the following criteria were met: (1) spontaneous labor; (2) delivery within 24 h of amniocentesis; (3) analysis of AF consistent with maturity; (4) birthweight >2500 g; and (5) absence of complications of prematurity and physical examination of the newborn by pediatricians consistent with a term neonate. A sample of AF was transported to the laboratory in a sterile capped syringe and cultured for aerobic/anaerobic bacteria and genital Mycoplasmas. White blood cell (WBC) count, glucose concentration and gram-stain were also performed shortly after collection as previously described [19–21]. The results of these tests were used for subsequent clinical management. AF IL-6 concentrations were employed only for research purposes. AF not required for clinical assessment was centrifuged for 10 min at 4°C, and the supernatant was aliquoted and stored at −70°C until analysis. Mid-trimester samples were not evaluated for markers of infection at the time of retrieval, however, all samples have subsequently been found to have an AF IL-6 concentration <2.6 ng/ml.

Placenta, umbilical cord and chorioamniotic membranes were collected in patients with spontaneous PTL and intact membranes who delivered within 72 h of amniocentesis, and the presence or absence of histologic chorioamnionitis and/or funisitis was assessed. The 72 h time period was chosen to preserve a meaningful temporal relationship between AF RBP4 concentrations and placental histopathologic findings.

Determination of retinol binding protein 4 concentration in amniotic fluid

AF concentration of RBP4 was determined by sensitive enzyme-linked immunoassays (Millipore Corporation, St. Charles, MO). The RBP4 immunoassay was validated for human AF in our laboratory, before the conduction of this study. Validation included spike and recovery experiments which produced parallel curves indicating that AF constituents did not interfere with antigen–antibody binding in this assay. Immunoassays were carried out according to the manufacturer's recommendations. AF samples were incubated in duplicate wells of the micro titer plates, which had been pre-coated with antibodies specific for the analyte (RBP4). During this incubation, the analyte present in the standards or AF samples was bound by the immobilized antibodies in the respective assay plates. After repeated washing and aspiration to remove all unbound substances, an enzyme-linked polyclonal antibody specific for the analyte was added to the wells of the assay plates. Unbound enzyme conjugate was removed by repeated washing and a substrate solution was added to the wells of the assay plates, with color developing in proportion to the amount of the analyte bound in the initial step. Color development was stopped with the addition of an acid solution, and the intensity of color was read using a programmable spectrophotometer (SpectraMax M2, Molecular Devices, Sunnyvale, CA). The concentrations of RBP4 in AF samples were determined by interpolation from individual standard curves. The calculated inter- and intra-assay coefficients of variation for RBP4 immunoassays in our laboratory were 6.98% and 6.05%, respectively. The sensitivity was calculated to be 0.09 ng/ml.

Statistical analysis

Shapiro–Wilk and Kolmogorov–Smirnov tests were used to test for normal distribution of the data. Since AF RBP4 concentrations were not normally distributed, non-parametric tests were used for analyses. Correlations between continuous variables were assessed by the Spearman's rank correlation test. Comparisons between proportions were performed with Chi-square test. Kruskal–Wallis with post-hoc test (Mann–Whitney U tests) was used for continuous variables. Among patients with PTL and intact membranes, a receiver–operating characteristic (ROC) curve analysis was performed to determine the AF RBP4 concentration cutoff for identification of patients who had IAI. A multivariable logistic regression model (stepwise) was utilized to examine the association between the RBP4 concentrations, maternal age, pre-pregnancy body mass index (BMI), smoking status, gestational age at amniocentesis and the presence of IAI. A p-value of <0.05 was considered statistically significant. Statistical analysis was performed with SPSS package version 12 (SPSS, Chicago, IL).

Results

Demographic and clinical characteristics of the study population

displays the demographic and clinical characteristics of patients in the mid-trimester, term not in labor and term in labor groups. presents the demographic and clinical characteristics of patients with spontaneous PTL and intact membranes. Among patients with PTL, those with IAI had a significantly lower median gestational age at amniocentesis than both patients without IAI who delivered preterm and those who delivered at term ().

Table I.  Demographic and clinical characteristics of women with normal pregnancies in the mid-trimester and at term, with and without spontaneous labor.

Table II.  Demographic and clinical characteristics among women presenting with spontaneous preterm labor (PTL) and intact membranes.

Amniotic fluid retinol binding protein 4 in normal pregnancies

RBP4 was detected in all AF samples (n = 271). The median AF RBP4 concentration in the mid-trimester was higher than in women at term not in labor (1861.1 ng/ml, interquartile range (IQR) 1486.2–2034.3 vs. 766.1 ng/ml, IQR 608.5–1154.1; p < 0.0001, ). Among women at term, the median AF RBP4 concentration did not differ significantly between women with spontaneous labor and those not in labor (term in labor: 836.8 ng/ml, IQR 589.5–1112.8; p = 0.4, ).

Figure 1.  Amniotic fluid concentrations of retinol-binding protein 4 (RBP4) in normal pregnancies in the mid-trimester and at term, in labor and not in labor. The median amniotic fluid RBP4 concentration was higher in women in the mid-trimester than in those at term not in labor [1861.1 ng/ml, interquartile range (IQR) 1486.2–2034.3 vs. 766.1 ng/ml, IQR 608.5–1154.1; p < 0.0001]. Among women at term, the median amniotic fluid RBP4 concentration did not differ significantly between women in labor and those not in labor (term not in labor: 766.1 ng/ml, IQR 608.5–1154.1 vs. term in labor: 836.8 ng/ml, IQR 589.5–1112.8; p = 0.4). The black lines represent the median and IQR.

Figure 1.  Amniotic fluid concentrations of retinol-binding protein 4 (RBP4) in normal pregnancies in the mid-trimester and at term, in labor and not in labor. The median amniotic fluid RBP4 concentration was higher in women in the mid-trimester than in those at term not in labor [1861.1 ng/ml, interquartile range (IQR) 1486.2–2034.3 vs. 766.1 ng/ml, IQR 608.5–1154.1; p < 0.0001]. Among women at term, the median amniotic fluid RBP4 concentration did not differ significantly between women in labor and those not in labor (term not in labor: 766.1 ng/ml, IQR 608.5–1154.1 vs. term in labor: 836.8 ng/ml, IQR 589.5–1112.8; p = 0.4). The black lines represent the median and IQR.

Amniotic fluid retinol binding protein 4 in spontaneous preterm labor and intact membranes

Among patients with PTL, the median AF RBP4 concentration differed significantly between the three study groups (Kruskal–Wallis, p < 0.001). Women with IAI had a higher median AF RBP4 concentration than those with PTL without IAI who delivered preterm (1268.9 ng/ml, IQR 900.3–1970.1 vs. 815.8 ng/ml, IQR 592.4–1098.1; p < 0.001) and those with PTL without IAI who delivered at term (828.7 ng/ml, IQR 499.7–1119.6; p < 0.001, ). The median AF RBP4 concentration did not differ significantly between patients with PTL without IAI who delivered preterm and those without IAI who delivered at term (p = 0.7, ).

Figure 2.  Amniotic fluid concentration of retinol-binding protein 4 (RBP4) among women with spontaneous preterm labor and intact membranes (PTL). The median amniotic fluid RBP4 concentration was higher in patients with intra-amniotic infection/inflammation (IAI) than in women with PTL without IAI who delivered preterm [1268.9 ng/ml, interquartile range (IQR) 900.3–1970.1 vs. 815.8 ng/ml, IQR 592.4–1098.1; p < 0.001], and than those with PTL without IAI who delivered at term (828.7 ng/ml, IQR 499.7–1119.6; p < 0.001). Among women with PTL without IAI, there was no difference in the median amniotic fluid concentration of RBP4 between those who delivered preterm and those who delivered at term (p = 0.7). The black lines represent the median and IQR.

Figure 2.  Amniotic fluid concentration of retinol-binding protein 4 (RBP4) among women with spontaneous preterm labor and intact membranes (PTL). The median amniotic fluid RBP4 concentration was higher in patients with intra-amniotic infection/inflammation (IAI) than in women with PTL without IAI who delivered preterm [1268.9 ng/ml, interquartile range (IQR) 900.3–1970.1 vs. 815.8 ng/ml, IQR 592.4–1098.1; p < 0.001], and than those with PTL without IAI who delivered at term (828.7 ng/ml, IQR 499.7–1119.6; p < 0.001). Among women with PTL without IAI, there was no difference in the median amniotic fluid concentration of RBP4 between those who delivered preterm and those who delivered at term (p = 0.7). The black lines represent the median and IQR.

The ROC curve of AF RBP4 concentration for the identification of IAI among patients with PTL with intact membranes is displayed in (area under the curve 0.71, p < 0.001). A cutoff value for AF RBP4 concentration of ≥1149.8 ng/ml had a sensitivity of 58.9% and a specificity of 79.8% for the identification of IAI in patients with PTL and intact membranes. In a backward stepwise multivariable logistic regression model including IAI as the dependent variable and maternal age, pre-pregnancy BMI, smoking status, gestational age at amniocentesis and AF RBP4 concentration as covariates, only an AF RBP4 concentration ≥1149.8 ng/ml and pre-pregnancy BMI were independently associated with the presence of IAI ().

Table III.  A backward stepwise, multivariable logistic regression model including IAI as the dependent variable and maternal age, pre-pregnancy BMI, smoking status, gestational age at amniocentesis and amniotic fluid RBP4 concentration ≥1149.8 ng/ml as covariates.

Figure 3.  Amniotic fluid concentrations of retinol-binding protein 4 (RBP4) among women with spontaneous preterm labor (PTL) and intra-amniotic infection/inflammation (IAI) who delivered within 72 h of amniocentesis and have placental histopathologic diagnosis. The median amniotic fluid RBP4 concentration was significantly higher in patients with IAI and histologic chorioamnionitis than in women with IAI without histologic chorioamnionitis [1901.0 ng/ml, interquartile range (IQR) 1107.3–2492.0 vs. 968.2 ng/ml, IQR 634.7–1396.7; p = 0.01]. The black lines represent the median and IQR.

Figure 3.  Amniotic fluid concentrations of retinol-binding protein 4 (RBP4) among women with spontaneous preterm labor (PTL) and intra-amniotic infection/inflammation (IAI) who delivered within 72 h of amniocentesis and have placental histopathologic diagnosis. The median amniotic fluid RBP4 concentration was significantly higher in patients with IAI and histologic chorioamnionitis than in women with IAI without histologic chorioamnionitis [1901.0 ng/ml, interquartile range (IQR) 1107.3–2492.0 vs. 968.2 ng/ml, IQR 634.7–1396.7; p = 0.01]. The black lines represent the median and IQR.

Among patients with PTL and intact membranes, the AF RBP4 concentrations correlated significantly with AF WBC count (r = 0.20, p = 0.007) and IL-6 concentrations (r = 0.37, p < 0.001), but not with AF glucose concentrations (r = −0.36, p = 0.6).

Amniotic fluid concentration of retinol binding protein 4 and placental inflammation

Among patients with spontaneous PTL and intact membranes with IAI, 75% (42/56) delivered within 72 h of amniocentesis, and placental histopathologic results were available from 74% (31/42) of those patients. The median AF RBP4 concentration was significantly higher in patients with IAI who had histologic chorioamnionitis and/or funisitis than in those without these placental lesions (1901.0 ng/ml, IQR 1107.3–2492.0 vs. 968.2 ng/ml, IQR 634.7–1396.7; p = 0.01, ).

Figure 4.  The receiver–operating characteristic (ROC) curve of amniotic fluid RBP4 concentration for the identification of IAI among patients with PTL with intact membranes (area under the curve (AUC) 0.71, p < 0.001). Derived from this ROC curve, a cutoff value for amniotic fluid RBP4 concentration of ≥1149.8 ng/ml had a sensitivity of 58.9% and a specificity of 79.8% for the identification of IAI in patients with PTL and intact membranes.

Figure 4.  The receiver–operating characteristic (ROC) curve of amniotic fluid RBP4 concentration for the identification of IAI among patients with PTL with intact membranes (area under the curve (AUC) 0.71, p < 0.001). Derived from this ROC curve, a cutoff value for amniotic fluid RBP4 concentration of ≥1149.8 ng/ml had a sensitivity of 58.9% and a specificity of 79.8% for the identification of IAI in patients with PTL and intact membranes.

Discussion

Principal findings of this study

(1) RBP4 was detected in all AF samples; (2) IAI in patients with PTL was associated with a higher median AF RBP4 than those without IAI; (3) The median AF RBP4 concentration was higher in the mid-trimester (14–18 weeks) than at term; (4) Spontaneous labor at term was not associated with changes in the median AF RBP4 concentration.

Retinol binding protein 4: an old carrier of retinol and a novel adipokine

Retinol binding protein, first described by Kanai et al. in 1968 [Citation22], is the specific carrier of retinol in the blood, belongs to the lipocalin (transporters for small hydrophobic molecules) family, and has a molecular weight of ∼21–22 kDa [Citation22]. RBP4 is a plasma protein [Citation23], whereas RBP1, RBP2 [Citation24], RBP5, and RBP7 are cellular proteins, and RBP3 is the interstitial form [Citation25].

Recently, RBP4, previously thought to play a role only in the delivery of retinol from the liver to peripheral tissues, has been classified as a novel adipokine implicated in the pathophysiology of insulin resistance [Citation3]. Several lines of evidence support this view: (1) the expression of the gene encoding RBP4 is increased in the adipose tissue of mice with adipocyte-specific ablation of GLUT4[Citation3]; (2) circulating RBP4 concentrations are significantly increased in humans with diabetes [Citation3]; (3) patients who are destined to develop type 2 diabetes mellitus have higher plasma/serum RBP4 concentrations before the development of overt disease [Citation7,Citation8] and (4) a high concentration of circulating RBP4 is an independent factor contributing to acute insulin response in obese subjects [Citation26]. Of note, other studies have not found an association between RBP4 and insulin resistance [Citation9,Citation10]. In addition, among non-diabetic men, the serum concentrations of RBP4 are not significantly different between lean, overweight and obese subjects, and circulating RBP4 concentrations are not associated with age, BMI, waist-to-hip ratio, or metabolic parameters, including insulin sensitivity [Citation26]. In summary, despite the fact that the role of RBP4 in diabetes and insulin resistance is controversial [Citation6], there is a growing body of evidence that supports the association between RBP4, metabolic complications and obesity-related disorders.

In addition to their suggested role in insulin resistance, adipocytokines have also been implicated in the pathophysiology of inflammatory disorders such as asthma [27–29], inflammatory bowel disease [30–32], rheumatoid arthritis [Citation33,Citation34], as well as obesity [3,6,11,35–44]. Moreover, some adipocytokines, such as resistin [Citation12],[Citation38],[Citation45,Citation46] and visfatin [Citation11],[Citation47,Citation48], have an immunoregulatory effect on the innate immune responses, while others (i.e. leptin) have been shown to regulate both the innate [49–52] and the adaptive limbs of the immune system [Citation53,Citation54]. Likewise, RBP4 [Citation1],[Citation6],[Citation12] has also been linked to inflammation. Indeed, RBP4 gene expression has been found to be strongly associated with inflammatory markers (i.e. CD68 and MCP-1) of adipose tissue in non-diabetic human subjects [Citation10].

Amniotic fluid retinol binding protein 4 concentrations in normal pregnancies

RBP4 was detectable in the AF of all patients included in this study, suggesting that RBP4 is a physiologic component of human AF. Moreover, RBP4 concentrations were higher in the mid-trimester than at term. These findings raise a question regarding the source of this protein in the AF. RBP in AF can be of maternal or fetal origin. In the rat fetal circulation, RBP and retinol concentrations increase in parallel from 11 to 14 days of gestation, and this has been suggested to result from the transplacental transport of retinol bound to RBP [Citation55]. Between 16 and 20 days of gestation, rat fetal concentrations of RBP increase significantly and this has been attributed to fetal synthesis of RBP [Citation55]. On the basis of these results, it has been suggested that maternal RBP-retinol can cross the placenta [Citation55,Citation56]. However, Quadro et al. [Citation57], using RBP-deficient (RBP −/−) mice and mice that express human RBP on the RBP −/− background, demonstrated that neither maternal nor fetal RBP crosses the placenta. Thus, AF RBP can be derived from either the fetus or membranes. Indeed, animal studies have demonstrated that RBP is synthesized by the amnion, chorion, and allantoic sac in the bovine [Citation58] as well as by the yolk sac and fetal liver in the rat [Citation59]. Furthermore, the latter report suggested that retinol transport to the fetus may involve RBP synthesized in the yolk sac and fetal tissues [Citation59].

The finding of higher mid-trimester concentrations of RBP4 in AF compared to term gestation is novel. This decrease of RBP4 concentration with advancing gestational age is similar to the pattern of alpha feto-protein, a fetus specific protein. The concentration of the latter decreases significantly from the second trimester of pregnancy to term gestation [Citation60,Citation61]. Thus, this finding further supports the concept of a fetal origin of AF RBP4.

Our finding of a higher mid-trimester concentration of RBP4 in AF compared to term is in apparent discrepancy with two previous reports by Sklan et al. [Citation56],[Citation59], which describe the AF concentrations of RBP4 at different gestational ages. In the rat, the AF concentrations of RBP (n = 12, radioimmunoassay) did not change significantly along gestation [Citation59]. Similarly, no significant differences were observed in the RBP concentrations determined by radial immunodiffusion in AF obtained from a total of 10 patients at 16–18 and 37–42 weeks of gestation [Citation56]. The small number of subjects and the different assays employed may account for this apparent inconsistency.

Amniotic fluid retinol binding protein 4 concentration is increased in women with preterm labor and intra-amniotic infection/inflammation

The increased RBP4 concentration in the AF of women with PTL and IAI reported herein is novel. This finding confirms a recent report from our group [Citation13] in which, using proteomic profiling of the AF of patients with PTL as a discovery tool, over-expression of RBP4 was observed in patients who delivered preterm when compared to those with an episode of PTL who delivered at term, regardless of the presence of IAI. RBP4 expression, however, was more profound in infected AF [Citation13]. Of note, we could not demonstrate a significant difference in the AF concentration of RBP4 between patients with PTL without IAI who delivered preterm or at term. Moreover, the lack of difference in the presence of term labor does not support a role for RBP4 in term or preterm parturition but, rather, in infection/inflammation.

The association between AF RBP4 concentrations and IAI in patients with spontaneous PTL and intact membranes is consistent with recent reports from our group concerning other adipokines such as visfatin [Citation11], resistin [Citation12], and adiponectin [Citation62], in which IAI was associated with increased AF adipokine concentrations. Moreover, the AF concentration of RBP4 was independently associated with IAI in patients with PTL and correlated with other indices of intra-amniotic inflammation such as AF WBC count (r = 0.20, p = 0.007) and IL-6 concentrations (r = 0.37, p < 0.001). In addition, the median AF RBP4 concentration was higher among patients with IAI and histologic chorioamnionitis and/or funisitis than among those with IAI without these placental lesions.

The cross-sectional nature of this study does not allow us to discern a cause and effect relationship between AF RBP4 and infection/inflammation. However, given the newly described role of RBP4 in the pathogenesis of insulin resistance, it is tempting to postulate that the higher RBP4 concentrations in AF are related to the increased fetal demand for energy in cases of IAI. In humans, insulin maintains normal glucose levels in the blood by binding to its receptor on the cell membrane, stimulating glucose uptake into muscle and fat cells through the GLUT4 transporter, as well as inhibition of glucose production in the liver. Yang et al. [Citation3] demonstrated that RBP4 may be the link between GLUT4 suppression and insulin resistance. Elevated concentrations of RBP4 impair insulin signaling in the muscle, inhibits glucose uptake, and interfere with insulin-mediated suppression of glucose production in the liver, causing elevation of blood glucose concentrations [Citation63]. Collectively, these findings may point to a role for RBP4 in the fetal inflammatory response to acute infection.

In conclusion, this study demonstrates that among patients with PTL, the AF concentration of immunoreactive RBP4 is elevated in pregnancies complicated with IAI and, to a greater extent, in cases with histological chorioamnionitis. These results suggest that the newly classified adipokine, RBP4, participates in the host response against intrauterine infection/inflammation.

Acknowledgements

This research was supported (in part) by the Perinatology Research Branch, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, DHHS.

References

  • Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772–783.
  • Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, Burley SK, Friedman JM. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543–546.
  • Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356–362.
  • Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, Hashimoto I, Okada T, Yasuhara A, Nakatsuka A, et al Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci USA 2005;102:10610–10615.
  • de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, et al Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007;56:1655–1661.
  • Tilg H, Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 2008;114:275–288.
  • Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, Lee HK, Park KS. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006;29:2457–2461.
  • Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, et al Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:2552–2563.
  • Janke J, Engeli S, Boschmann M, Adams F, Bohnke J, Luft FC, Sharma AM, Jordan J. Retinol-binding protein 4 in human obesity. Diabetes 2006;55:2805–2810.
  • Yao-Borengasser A, Varma V, Bodles AM, Rasouli N, Phanavanh B, Lee MJ, Starks T, Kern LM, Spencer HJ III, Rashidi AA, et al Retinol binding protein 4 expression in humans: relationship to insulin resistance, inflammation, and response to pioglitazone. J Clin Endocrinol Metab 2007;92:2590–2597.
  • Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Gotsch F, Mittal P, Than NG, Nhan-Chang CL, Hamill N, Vaisbuch E, et al Visfatin/Pre-B cell colony-enhancing factor in amniotic fluid in normal pregnancy, spontaneous labor at term, preterm labor and prelabor rupture of membranes: an association with subclinical intrauterine infection in preterm parturition. J Perinat Med 2008;36:485–496.
  • Kusanovic JP, Romero R, Mazaki-Tovi S, Chaiworapongsa T, Mittal P, Gotsch F, Erez O, Vaisbuch E, Edwin SS, Than NG, et al Resistin in amniotic fluid and its association with intra-amniotic infection and inflammation. J Matern Fetal Neonatal Med 2008;21:902–916.
  • Bujold E, Romero R, Kusanovic JP, Erez O, Gotsch F, Chaiworapongsa T, Gomez R, Espinoza J, Vaisbuch E, Mee KY, et al Proteomic profiling of amniotic fluid in preterm labor using two-dimensional liquid separation and mass spectrometry. J Matern Fetal Neonatal Med 2008;21:697–713.
  • Alexander GR, Himes JH, Kaufman RB, Mor J, Kogan M. A United States national reference for fetal growth. Obstet Gynecol 1996;87:163–168.
  • Gonzalez RP, Gomez RM, Castro RS, Nien JK, Merino PO, Etchegaray AB, Carstens MR, Medina LH, Viviani PG, Rojas IT. A national birth weight distribution curve according to gestational age in Chile from 1993 to 2000. Rev Med Chil 2004;132:1155–1165.
  • Yoon BH, Romero R, Moon JB, Shim SS, Kim M, Kim G, Jun JK. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. Am J Obstet Gynecol 2001;185:1130–1136.
  • Pacora P, Chaiworapongsa T, Maymon E, Kim YM, Gomez R, Yoon BH, Ghezzi F, Berry SM, Qureshi F, Jacques SM, et al Funisitis and chorionic vasculitis: the histological counterpart of the fetal inflammatory response syndrome. J Matern Fetal Neonatal Med 2002;11:18–25.
  • Redline RW. Inflammatory responses in the placenta and umbilical cord. Semin Fetal Neonatal Med 2006;11:296–301.
  • Romero R, Emamian M, Quintero R, Wan M, Hobbins JC, Mazor M, Edberg S. The value and limitations of the Gram stain examination in the diagnosis of intraamniotic infection. Am J Obstet Gynecol 1988;159:114–119.
  • Romero R, Jimenez C, Lohda AK, Nores J, Hanaoka S, Avila C, Callahan R, Mazor M, Hobbins JC, Diamond MP, et al Amniotic fluid glucose concentration: a rapid and simple method for the detection of intraamniotic infection in preterm labor. Am J Obstet Gynecol 1990;163:968–974.
  • Romero R, Quintero R, Nores J, Avila C, Mazor M, Hanaoka S, Hagay Z, Merchant L, Hobbins JC. Amniotic fluid white blood cell count: a rapid and simple test to diagnose microbial invasion of the amniotic cavity and predict preterm delivery. Am J Obstet Gynecol 1991;165:821–830.
  • Kanai M, Raz A, Goodman DS. Retinol-binding protein: the transport protein for vitamin A in human plasma. J Clin Invest 1968;47:2025–2044.
  • Rocchi M, Covone A, Romeo G, Faraonio R, Colantuoni V. Regional mapping of RBP4 to 10q23–q24 and RBP1 to 3q21–q22 in man. Somat Cell Mol Genet 1989;15:185–190.
  • Demmer LA, Birkenmeier EH, Sweetser DA, Levin MS, Zollman S, Sparkes RS, Mohandas T, Lusis AJ, Gordon JI. et al The cellular retinol binding protein II gene. Sequence analysis of the rat gene, chromosomal localization in mice and humans, and documentation of its close linkage to the cellular retinol binding protein gene. J Biol Chem 1987;262:2458–2467.
  • Liou GI, Fong SL, Gosden J, van TP, Ledbetter DH, Christie S, Rout D, Bhattacharya S, Cook RG, Li Y, et al Human interstitial retinol-binding protein (IRBP): cloning, partial sequence, and chromosomal localization. Somat Cell Mol Genet 1987;13:315–323.
  • Broch M, Vendrell J, Ricart W, Richart C, Fernandez-Real JM. Circulating retinol-binding protein-4, insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects. Diabetes Care 2007;30:1802–1806.
  • Gurkan F, Atamer Y, Ece A, Kocyigit Y, Tuzun H, Mete N. Serum leptin levels in asthmatic children treated with an inhaled corticosteroid. Ann Allergy Asthma Immunol 2004;93:277–280.
  • Guler N, Kirerleri E, Ones U, Tamay Z, Salmayenli N, Darendeliler F. Leptin: does it have any role in childhood asthma?. J Allergy Clin Immunol 2004;114:254–259.
  • Shore SA, Schwartzman IN, Mellema MS, Flynt L, Imrich A, Johnston RA. Effect of leptin on allergic airway responses in mice. J Allergy Clin Immunol 2005;115:103–109.
  • Barbier M, Vidal H, Desreumaux P, Dubuquoy L, Bourreille A, Colombel JF, Cherbut C, Galmiche JP. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol 2003;27:987–991.
  • Siegmund B, Sennello JA, Lehr HA, Batra A, Fedke I, Zeitz M, Fantuzzi G. Development of intestinal inflammation in double IL-10- and leptin-deficient mice. J Leukoc Biol 2004;76:782–786.
  • Tuzun A, Uygun A, Yesilova Z, Ozel AM, Erdil A, Yaman H, Bagci S, Gulsen M, Karaeren N, Dagalp K, . Leptin levels in the acute stage of ulcerative colitis. J Gastroenterol Hepatol 2004;19:429–432.
  • Schaffler A, Ehling A, Neumann E, Herfarth H, Tarner I, Scholmerich J, Muller-Ladner U, Gay S. Adipocytokines in synovial fluid. JAMA 2003;290:1709–1710.
  • Bernotiene E, Palmer G, Talabot-Ayer D, Szalay-Quinodoz I, Aubert ML, Gabay C. Delayed resolution of acute inflammation during zymosan-induced arthritis in leptin-deficient mice. Arthritis Res Ther 2004;6:R256–R263.
  • Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815–3819.
  • Esposito K, Pontillo A, Di PC, Giugliano G, Masella M, Marfella R, Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003;289:1799–1804.
  • Frayn KN. Obesity and metabolic disease: is adipose tissue the culprit?. Proc Nutr Soc 2005;64:7–13.
  • Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005;174:5789–5795.
  • Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes Rev 2007;8:21–34.
  • Nien JK, Mazaki-Tovi S, Romero R, Erez O, Kusanovic JP, Gotsch F, Pineles BL, Gomez R, Edwin S, Mazor M, et al Plasma adiponectin concentrations in non-pregnant, normal and overweight pregnant women. J Perinat Med 2007;35:522–531.
  • Nien JK, Mazaki-Tovi S, Romero R, Erez O, Kusanovic JP, Gotsch F, Pineles BL, Gomez R, Edwin S, Mazor M, et al Adiponectin in severe preeclampsia. J Perinat Med 2007;35:503–512.
  • Nien JK, Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Gotsch F, Pineles BL, Friel LA, Espinoza J, Goncalves L, et al Resistin: a hormone which induces insulin resistance is increased in normal pregnancy. J Perinat Med 2007;35:513–521.
  • Mazaki-Tovi S, Romero R, Kusanovic JP, Vaisbuch E, Erez O, Than NG, Chaiworapongsa T, Nhan-Chang CL, Pacora P, Gotsch Fet al Visfatin in human pregnancy: maternal gestational diabetes vis-a-vis neonatal birthweight. J Perinat Med 2009;37:218–231.
  • Mazaki-Tovi S, Romero R, Kusanovic JP, Erez O, Vaisbuch E, Gotsch F, Mittal P, Than GN, Nhan-Chang C, Chaiworapongsa T, et al Adiponectin multimers in maternal plasma. J Matern Fetal Neonatal Med 2008;21:796–815.
  • Verma S, Li SH, Wang CH, Fedak PW, Li RK, Weisel RD, Mickle DA. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 2003;108:736–740.
  • Silswal N, Singh AK, Aruna B, Mukhopadhyay S, Ghosh S, Ehtesham NZ. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-κB-dependent pathway. Biochem Biophys Res Commun 2005;334:1092–1101.
  • Ognjanovic S, Bryant-Greenwood GD. Pre-B-cell colony-enhancing factor, a novel cytokine of human fetal membranes. Am J Obstet Gynecol 2002;187:1051–1058.
  • Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004;113:1318–1327.
  • Gainsford T, Willson TA, Metcalf D, Handman E, McFarlane C, Ng A, Nicola NA, Alexander WS, Hilton DJ. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc Natl Acad Sci USA 1996;93:14564–14568.
  • Tian Z, Sun R, Wei H, Gao B, . Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation. Biochem Biophys Res Commun 2002;298:297–302.
  • Matarese G, Moschos S, Mantzoros CS. Leptin in immunology. J Immunol 2005;174:3137–3142.
  • Zhao T, Hou M, Xia M, Wang Q, Zhu H, Xiao Y, Tang Z, Ma J, Ling W. Globular adiponectin decreases leptin-induced tumor necrosis factor-alpha expression by murine macrophages: involvement of cAMP-PKA and MAPK pathways. Cell Immunol 2005;238:19–30.
  • Lord GM, Matarese G, Howard JK, Baker RJ, Bloom SR, Lechler RI. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998;394:897–901.
  • Howard JK, Lord GM, Matarese G, Vendetti S, Ghatei MA, Ritter MA, Lechler RI, Bloom SR. Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice. J Clin Invest 1999;104:1051–1059.
  • Takahashi YI, Smith JE, Goodman DS. Vitamin A and retinol-binding protein metabolism during fetal development in the rat. Am J Physiol 1977;233:E263–E272.
  • Sklan D, Shalit I, Lasebnik N, Spirer Z, Weisman Y. Retinol transport proteins and concentrations in human amniotic fluid, placenta, and fetal and maternal sera. Br J Nutr 1985;54:577–583.
  • Quadro L, Hamberger L, Gottesman ME, Colantuoni V, Ramakrishnan R, Blaner WS. Transplacental delivery of retinoid: the role of retinol-binding protein and lipoprotein retinyl ester. Am J Physiol Endocrinol Metab 2004;286:E844–E851.
  • Liu KH, Baumbach GA, Gillevet PM, Godkin JD. Purification and characterization of bovine placental retinol-binding protein. Endocrinology 1990;127:2696–2704.
  • Sklan D, Ross AC. Synthesis of retinol-binding protein and transthyretin in yolk sac and fetus in the rat. J Nutr 1987;117:436–442.
  • Seppala M, Ruoslahti E. alpha fetoprotein in amniotic fluid: an index of gestational age. Am J Obstet Gynecol 1972;114:595–598.
  • Seppala M, Ruoslahti E. alpha-fetoprotein in antenatal diagnosis. Lancet 1973;20:155
  • Mazaki-Tovi S, Romero R, Vaisbuch E, Kusanovic JP, Erez O, Mittal P, Gotsch F, Chaiworapongsa T, Than NG, Kim SK, et al Adiponectin in amniotic fluid in normal pregnancy, spontaneous labor at term, and preterm labor: A novel association with subclinical intrauterine infection/inflammation. J Matern. Fetal Neonatal Med 2009; In Press.
  • Muoio DM, Newgard CB. Metabolism: A is for adipokine. Nature 2005;436:337–338.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.